Trastuzumab Biosimilars Market Report 2026

Trastuzumab Biosimilars Market Overview

• Trastuzumab Biosimilars market size has reached to $6.9 billion in 2025 • Expected to grow to $24.48 billion in 2030 at a compound annual growth rate (CAGR) of 28.9% • Growth Driver: Rising Breast And Gastric Cancer Prevalence Drives Trastuzumab Biosimilars Market. • Market Trend: Companies Focus On Product Launches And Expansion To Fuel Trastuzumab Biosimilars Market Growth • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Trastuzumab Biosimilars Market?

Trastuzumab biosimilar refers to a HER2-targeted therapy drug that is designed to treat early and metastatic HER2-positive breast cancers. Trastuzumab biosimilar is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2)/neu receptor and renders it inactive The main types of products in the trastuzumab biosimilars are ogivri, herzuma, ontruzant, trazimera, and others. The different indications include adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, and others, and they are distributed through hospital pharmacies and online pharmacies.

What Is The Trastuzumab Biosimilars Market Growth Forecast?

The trastuzumab biosimilars market size is expected to see exponential growth in the next few years. It will grow to $24.48 billion in 2030 at a compound annual growth rate (CAGR) of 28.9%. The growth in the forecast period can be attributed to increasing cancer prevalence, expansion into gastric cancer indications, favorable reimbursement for biosimilars, growing physician confidence, rising healthcare cost containment efforts. Major trends in the forecast period include rapid uptake of oncology biosimilars, improved access to HER2 targeted therapies, price competition in breast cancer treatment, expansion of hospital oncology use, growing acceptance of biosimilar switching.

Global Trastuzumab Biosimilars Market Segmentation

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products 2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

What Is The Driver Of The Trastuzumab Biosimilars Market?

The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilars market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, about 297,790 new cases of invasive breast cancer will be diagnosed in women in 2023, and about 43,700 women will die from breast cancer in the same year. According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that help save money when compared to expensive medicines, thereby driving the trastuzumab biosimilars industry.

Key Players In The Global Trastuzumab Biosimilars Market

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Torrent Pharmaceuticals Limited

Global Trastuzumab Biosimilars Market Trends and Insights

Major players are continuously focusing on launching new products in untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives, such as new product development, partnerships, and geographical and product portfolio expansion, to maintain their competitive position in the market and better serve the needs of the customers. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab) for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI is prescribed for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers are generally aggressive but respond effectively to targeted therapies. HERCESSI works by binding to the HER2 receptor, inhibiting its activity and thereby slowing down the replication of cancer cells.

What Are Latest Mergers And Acquisitions In The Trastuzumab Biosimilars Market?

In June 2025, Alvotech, an Iceland‑based biotech company, acquired Xbrane Biopharma AB for an amount of $28.9 million. With this acquisition, Alvotech aims to bolster its R&D capabilities and establish a stronger foothold in the Swedish life‑science ecosystem. Xbrane Biopharma AB is a Sweden‑based biopharmaceutical firm specializing in developing biosimilars and long‑acting injectables.

Regional Insights

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Trastuzumab Biosimilars Market?

The trastuzumab biosimilars market consists of sales of herceptin, avastin, and Kanjinti. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Trastuzumab Biosimilars Market Report 2026?

The trastuzumab biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the trastuzumab biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.